Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06572267 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease

Study acronym: REC-SAFECAD
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 23, 2026 (before its estimated September 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Sep 1, 2025 to Sep 1, 2026
    • Study completion date: Mar 1, 2026 to Mar 1, 2027
    v3
  2. Start date changed from estimate of Aug 26, 2024 to Oct 16, 2024
    • Eligibility criteria shortened, about 12 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The development of coronary atherosclerosis is closely related to inflammation, and CD147 may play an important role in its process. The present study was designed to evaluate the effects of long-term administration of mepolizumab (humanized anti-CD147 antibody) on lipid deposition and inflammation in coronary atherosclerotic plaques in patients with high-risk coronary artery disease, and to preliminarily explore the efficacy, safety, and dosage of long-term administration of mepolizumab in this population.
Trial Details
NCT Number NCT06572267
Lead Sponsor Xijing Hospital
Conditions
(from sponsor)		 Coronary Artery Disease
Related terms Coronary Artery Disease, Inflammation
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov